STATE OF THE SECTOR - djpr.vic.gov.au · Number of listed Victorian life science companies (2015) 15 Figure 12. Capitalisation of listed Victorian life science companies excluding

STATE OF THE SECTORMedical Technologies and Pharmaceuticals 2017

Published by the Department of Economic Development, Jobs, Transport and Resources 1 Spring Street Melbourne, Victoria 3000 Telephone (03) 9208 3799

July 2017

© Copyright State Government of Victoria 2017 This publication is copyright. No part may be reproduced by any process except in accordance with provisions of the Copyright Act 1968.

Authorised by the Victorian Government, Melbourne.

Designed by DEDJTR Design Studio

ISBN 978-1-925629-62-0 (pdf/online)

Accessibility

If you would like to receive this publication in an accessible format, such as large print or audio, please email [email protected]. This publication is also published in PDF and Word formats on http://economicdevelopment.vic.gov.au/victorian-economy-in-focus/priority-industries-sectors/medical-technologies- and-pharmaceuticals

Cover photo Staff at Grey Innovation

3 /STATE OF THE SECTOR | MEDICAL TECHNOLOGIES AND PHARMACEUTICALS

MiniFab

ContentsIntroduction 6

Key findings 7

The economic impact of the sector 10

Further information 19

Notes on methodology 20

Table 1. Summary of sector metrics 7

Figure 1. Representative sector supply chain 8

Figure 2. Key medtech and pharmaceutical business locations 9

Figure 3. Key economic aggregates for the sector (2013-14) 10

Figure 4. Total revenue generated by Victorian companies (2015) 10

Figure 5. Sector export data (goods exports only, 2016) 11

Figure 6. Annual average exports by market 2011-2016 11

Figure 7. Supply chain analysis. 12

Figure 8. Wages and employment in the sector (2013-14) 13

Figure 9. Manufacturing employment trends in the sector (2016) 13

Table 2. Company employment ranges for Victorian companies surveyed (2015) 14

Figure 10. Aggregate capitalisation of listed Victorian companies 14

Figure 11. Number of listed Victorian life science companies (2015) 15

Figure 12. Capitalisation of listed Victorian life science companies excluding Sigma Pharmaceuticals Ltd and CSL (2015) 15

Figure 13. Share of ASX market capitalisation by location of registered company offices (June 2016) 16

Figure 14. Total R&D spending by Victorian companies (2015) 17

Table 3. Outcomes by state and territory for competitive grants awarded in the 2016 application round 17

Figure 15. Victorian strengths (June 2016) 18

Figure 16. Asset development in Victoria – drugs and medical devices (June 2016) 18

Melbourne Brain Centre


Ministers’ ForewordWe are pleased to present the Victorian Government’s first State of the Sector overview for medical technologies and pharmaceuticals. Medical technologies and pharmaceuticals is a growth sector vital to the future economic prosperity of Victoria and a source of employment for Victorians.

Innovation is critical to developing new sources of growth through creation of new businesses, new jobs and increased productivity. The medical technologies and pharmaceuticals sector provides Victoria with a springboard for innovation-based opportunities.

Since the release of the Victorian Government’s Medical Technologies and Pharmaceuticals Sector Strategy, we have provided key support to industry and manufacturing through the Future Industries Fund. This has included funding for BioCurate and the Medicines Manufacturing Innovation Centre to accelerate the development and commercialisation of new medicines, and further boost Victoria's pharmaceutical manufacturing capability. It has also included provision of grants to a range of Victorian medtech and pharmaceutical manufacturers such as Medical Developments International, Komipharm and DorsaVi. We have also commissioned the first comprehensive analysis of this important sector, culminating in this report.

Australia is one of the world’s leading locations for the development and manufacture of medical technologies, biotechnologies and pharmaceuticals.

Victoria is at the epicentre of this dynamic sector, employing more than 23,000 people, and generating over $12.7 billion in revenue. The sector contributes over $1.35 billion in exports to the Victorian economy, a figure which has doubled since 2011.

Melbourne has a reputation as the leading hub for Australia’s medical technologies industry. The biomedical engineering expertise in the State builds on a long tradition in automotive, aerospace and general manufacturing expertise and is enhanced by significant capabilities in advanced, additive and bio-manufacturing.

With global health care spending projected to grow by over four per cent per year, there is an urgent need for new technologies, goods and services that will improve patient care. This is an enormous and continued economic opportunity for Victoria.

This State of the Sector report demonstrates that the sector’s economic impact is significant and positive. This publication provides us with a better understanding of how the sector is growing and will enable the Victorian Government and the sector to measure our efforts and better understand where we need to direct our energy. Continuing to grow the medical technologies and pharmaceuticals sector will create rewarding, high value, secure jobs for Victorians and help us play a key role in improving health and wellbeing worldwide.

Wade Noonan Minister for Industry and Employment

Jill Hennessy Minister for Health

Philip Dalidakis Minister for Small Business, Innovation and Trade

Introduction

This report brings together four sources of data:

• an analysis of the economic impact of the medtech and pharmaceuticals sector on the Victoria economy, conducted by the Centre for Transformative Innovation (CTI) at Swinburne University, utilising BLADE data1;

• annual survey data, compiled by Blake Industry and Market Analysis Pty. Ltd.;

• market capitalisation information, sourced from the ASX; and

• export commodity trade data, sourced from the IHS Global Trade Atlas.

This publication provides a summary of the results of these reports, together with proprietary government department data as appropriate. Notes on the methodology can be found at the end of this report.

1 Determining the economic impact of the sector is made possible by the Australian Bureau of Statistics Business Longitudinal Data Environment (BLADE). This database is the only comprehensive data of financial operations of every business in Australia and is based on annual business tax file records and survey data. The measure of economic impact, total value added, is calculated by aggregating across all firms in the sector

360 Biolabs

STATE OF THE SECTOR | MEDICAL TECHNOLOGIES AND PHARMACEUTICALS

Introduction

In 2013-14, the Sector generated $12.7 billion in revenue and employed 23,000 people.The following table provides a summary of the sector metrics:

Table 1. Summary of sector metrics

Sector revenue $12.7 billion

Sector-value added $2.2 billion

Exports $1.35 billion2

Percentage of Victoria's total state exports

3.5 per cent

Total capital investment $276 million

Number of employees 23,000 employees (18,000 FTE)

Average wage of employees

$74,000 /employee

Source: Centre for Transformative Innovation

2

2 Statistic from the IHI Global Trade Atlas

Describing and defining the sector For the purposes of this report the sector is defined as firms engaged in the following activities:

1. Pharmaceutical manufacturing and development

2. Life science and biotechnology manufacturing and development

3. Medical technology manufacturing and development

4. Vitamins, supplements and topical product manufacturing and development

5. Service providers – contract research organisations, clinical trial providers, etc.

The sector can be defined as firms that are interconnected and that have shared success factors, supporting industries, infrastructure or labour markets. A representative sector supply chain is depicted in blue in Figure 1.

Firms active in the sector in Victoria may be involved in activities from basic science through to wholesale trade. Firms in the sector perform activities across a range of industry sectors defined in the Australian and New Zealand Standard Industry Classifications or ANZSIC codes.3 Please note that relevant activity undertaken in universities and hospitals was excluded from the analysis.4

3 It is not possible to directly use industry level statistics on economic activity collected by the ABS. This is because the sector comprises incomplete parts of several ANZSICs. To measure the impact of the Sector on the Victorian economy, a comprehensive list of relevant active firms was developed.

4 The main reason for excluding universities and hospitals is that it is not possible to separately identify sector relevant activities from the main activities of these organisations (education and health care) which are not part of the sector.

Key findings

7 /

Hudson Institute

Basic Science

Manufacture Wholesale

Imports

ExportsOffshore

Development & Commercialisation

Licence &

FDI

Invention Disclosure & Applied Research

Retail & Health Service

Providers (Pharmacies,

GPs, etc.)

Development & Commercialisation

Figure 1. Representative sector supply chain5

5 Size of circles are not indicative of the relative size of the sectoral component


Size and location of the sectorThe medical technologies and pharmaceuticals sector is largely located in the Melbourne Metropolitan area – 84 per cent of total businesses. There are a large numbers of businesses in the East, South East and CBD, with growing numbers in the West. While the sector is located primarily in greater Melbourne, there are some firms that are located in regional areas, mainly Geelong.

Notably, there are geographical clusters of medical technologies and pharmaceuticals sector firms. These clusters are around the inner metropolitan region, the Clayton and Monash University precinct, the Ringwood/Bayswater area, and the Dandenong/Mulgrave manufacturing precinct, see Figure 2.

Cranbourne

Deer Park

Belgrave

Berwick

Box Hill

Mornington

Bunyip

Tooradin

Melbourne

Bacchus Marsh

Hurstbridge

Craigieburn

Dandenong

Yarra Junction

Caroline Springs

Healesville

Powelltown

Yarra Glen

WarburtonWarrandyte

Werribee

Ocean Grove

Sunbury

Portarlington

Queenscliff Lang Lang

Pakenham

Tullamarine

Lilydale

Melton

Geelong

Heidelberg

Moorabbin

Frankston

Figure 2. Key medtech and pharmaceutical business locations

Source: DEDTJR, Commercial-in-Confidence

The economic impact of the sector

Direct impact/revenueRevenue, operating expenses and value-added for financial years 2013-14 are depicted in Figure 3. These show sector revenue of around $12.7 billion, with an average salary of $74,000 per annum. Operating expenses of $10.5 billion were reported, resulting in total value add to the Victorian economy of nearly $2.2 billion.6

RevenueAccording to Blake, revenue from Victorian companies increased 20.7 per cent in 2015, to approximately $12 billion, see Figure 4. This is broadly consistent with the findings from the Centre for Transformative Innovation.

6 Value added is equal to turnover net of intermediate inputs. This is consistent with the approach for calculating GDP or Gross State Product (GSP).

Re

ven

ue

: 12.

7

Op

era

tin

g e

xp

en

ses:

10

.5

Va

lue

ad

de

d: 2

.17

2.0

0

4.0

6.0

8.0

10.0

12.0

14.0

$b

illio

n

0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

($b

illio

n)

Figure 3. Key economic aggregates for the sector (2013-14)

Figure 4. Total revenue generated by Victorian companies (2015)


Source: Blake Industry & Market Analysis


ExportsThe sector contributed over $1.35 billion in exports over 2013-14. This is a measure of goods exports only, not licensing, services, IP etc. (Centre for Transformative Innovation). This accounted for just over 3.5 per cent of a Victorian total of $24 billion over the same period.

EXPORT DATA (LONGITUDINAL, AND BY MARKET)

2016 figures indicate that there has been a significant improvement in export figures, driven mainly by growth in pharma sales see Figure 5. The majority of exports go to the USA and Europe. See Figure 6.

Financial year

Pharma exports MedTech exports

2011 2012 2013 2014 2015 2016

Va

lue

of

Vic

tori

a's

Med

Tec

h

& P

ha

rma

Exp

ort

s ($

m)

50 55

7167

77

78

0

300

600

900

1200

1500

605 628

725682

749

1,267

Figure 5. Sector export data (goods exports only, 2016)

Source: IHS Global Trade Atlas: Global Import/Export Commodity Trade Data, 2016

Source: IHS Global Trade Atlas: Global Import/Export Commodity Trade Data, 2016

Figure 6. Annual average exports by market 2011-2016

United States

Europe

South East Asia

East Asia, inc China

MENA

NZ & the Pacific

Canada

Central and SouthAmerica, inc Carribean

South Asiainc India

Africa

Supply chain effectsThe sector also contributes to aggregate demand in sectors that supply intermediate inputs. The CTI Report estimates that the Sector contributes $6.9 billion in upstream demand to other sectors in the Victorian economy.

The detailed breakdown of the distribution of sources of intermediate inputs is presented in Figure 7. Supplying industries are aggregated to the ANZSIC Division level. Transport, Postal and Warehousing is the largest supplying industry group to the sector, supplying nearly $1.5 billion of intermediate inputs. Rental, Hiring and Real Estate Services ($1.2 billion) and Manufacturing ($0.99 billion) are the next largest contributors.7

7 Nearly one fifth of the sectors’ operating expenditure falls under the category Within Sector. This group captures the expenditure on intermediate inputs by the sector from within the sector. Inputs purchased by other firms in the Sector will be reflected in the supplying firm turnover. Therefore, this economic impact has already been captured in the value added measure.

,

$0 $500 $1,000 $1,500 $2,000 $2,500

AN

ZS

IC D

ivis

ion

$million

Within sector: $2,094

Imports: $1,418

Other: $763.88

Retail trade: $210

Construction: $459

Administrative and support services: $555

Financial and insurance services: $593

Manufacturing: $995

Rental, hiring and real estate services: $1,196

Transport, postal and warehousing: $1,526

Electricity, gas, water and waste services: $237

Information media and telecommunications: $454

Figure 7. Supply chain analysis.


Walter and Eliza Hall Institute


Wages and employmentTotal sector employment is just under 23,000 individuals, with just over 18,000 full time equivalent (FTE) positions (Figure 8). Firms in the sector paid $1.34 billion in remuneration in the year 2013-14. Manufacturing employment in the sector has also steadily increased over time, see Figure 9.

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

10000

Nu

mb

er o

f Em

plo

yees

(H

ead

cou

nt)

1985

1986

1987

1988

1989

199

019

91

199

219

93

199

419

95

199

619

97

199

819

99

200

020

01

200

220

03

200

420

05

200

620

07

200

820

09

2010

2011

2012

2013

2014

2015

Figure 9. Manufacturing employment trends in the sector (2016)

FT

E: 1

8,3

24

He

ad

cou

nt:

22,

89

4

Wa

ge

s: $

1,3

44

$200

$0

$400

$600

$800

$1,000

$1,200

$1,400

$1,600

5,000

0

10,000

15,000

20,000

25,000

$m

illio

n

Nu

mb

er

Figure 8. Wages and employment in the sector (2013-14)

Source: DEDTJR, drawing on ABS data


Employment ranges for Victorian companies in the sectorEmployment ranges for the surveyed Victorian companies in the sector are summarised in Table 2.8

Capitalisation and listing of the sectorThe aggregate capitalisation of listed Victorian companies in 2015 was $43.9 billion, having risen sharply since 2011, see Figure 10. Note that the key driver of change was CSL, which increased in market value by $5 billion to $40.1 billion from 2006 to 2015. NB: At 26 April 2017, the aggregate capitalisation was approximately $55.2 billion.

8 Blake Industry & Market Analysis Pty Ltd (21 October, 2016), Medical Technology & Pharmaceutical Sector 2015 Final Annual Report. Commercial in confidence.

Table 2. Company employment ranges for Victorian companies surveyed (2015)

Number of employees

Listed companies Private companies Total

<20 16 102 118

20 – 50 8 27 35

50 – 200 8 12 20

200+ 4 4 8


Figure 10. Aggregate capitalisation of listed Victorian companies

16.4

21.7

25.423.8

21.4

20.4

27.7

34.1

35.8

38.039.0

43.9

10

15

20

25

30

35

40

45

50

($B

illio

n)

Sept2006

Sept2007

Sept2008

Sept2009

Sept2010

Sept2011

Sept2012

Sept2013

Sept2014

Sept2015


STATE OF THE SECTOR | MEDICAL TECHNOLOGIES AND PHARMACEUTICALS

VICTORIAN ASX LISTED COMPANIES AND MARKET CAP

36 listed Victorian companies had a market capitalisation at June 30, 2015 of $43.9 billion (up from $39.0 billion in 2014). The number of Victorian life science companies listed on the ASX has fallen since 2008-9 and has remained static since 2011, see Figure 11.

Note that when Sigma Pharmaceuticals Limited and CSL are excluded from the data, market capitalisation has fallen significantly, since 2011, see Figure 12. This is largely as a result of lower investment capital after the Global Financial Crisis.

2.5

3.5

2.0

2.92.8

4.3

3.8

3.8

3.9

3.7

2.92.9

1

1.5

2

2.5

3

3.5

4

4.5

5

($B

illio

n)

Sept2006

Sept2007

Sept2008

Sept2009

Sept2010

Sept2011

Sept2012

Sept2013

Sept2014

Sept2015

Jun2005

Jun2006

Jun2007

Jun2008

Mar2009

Sep2009

Sep2010

Mar2011

Sep2011

Mar2012

Sep2012

Mar2013

Sep2013

Mar2014

Sep2014

Jun2015

42 42

44

4847

44

4241

36 36 36

3435

34 34 34

Figure 11. Number of listed Victorian life science companies (2015)

Figure 12. Capitalisation of listed Victorian life science companies excluding Sigma Pharmaceuticals Ltd and CSL (2015)



15 /

SHARE OF ASX MARKET CAPITALISATION BY STATE

Victoria dominates company market capitalisation on the ASX, see Figure 13.

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Pharma MedTech Total

Sh

are

of M

ark

et C

ap

ita

lisa

tio

n (%

)

60.2%45.7%

92.4%

4.0%3.4%

11.6%

28.0%

12.5%

2.2%

20.6%

11.2%

2.9%5.1%

VIC

NSW

USA

NZ

Other Australianstates

Figure 13. Share of ASX market capitalisation by location of registered company offices (June 2016)

360 Biolabs


Total research and development (R&D) investmentR&D spending in Victoria, with the notable exception of CSL and Mesoblast Ltd, has fallen since 2010, see Figure 14.

NATIONAL HEALTH & MEDICAL RESEARCH COUNCIL (NHMRC)

Victoria is the leading state in competitive grant outcomes,9 see Table 3, with almost 42% of total NHMRC funding in 2016.

9 nhmrc.gov.au/grants-funding/outcomes-funding-rounds, accessed February 2017.

Table 3. Outcomes by state and territory for competitive grants awarded in the 2016 application round

State Applications FundedFunded

rate AmountPercentage

of funding

VIC 2,108 421 20.0% $329,655,050 41.8%

NSW 1,525 272 17.8% $227,547,908 28.9%

QLD 825 131 15.9% $111,543,419 14.1%

WA 360 58 16.1% $44,095,650 5.6%

SA 493 64 13.0% $40,617,469 5.1%

ACT 115 25 21.7% $19,731,441 2.5%

NT 33 8 24.2% $10,213,405 1.3%

TAS 60 7 11.7% $5,016,753 0.6%

Total 5,519 986 17.9% $788,421,095

262 283310

416454

528555

653 637 619657

744

835

969

171 190 209

269 284330 321 328 309

267

215 189226 216

100

0

200

300

400

500

600

700

800

900

1,000

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

R&

D S

pen

d ($

M)

Total Exc. CSL & MSB

Figure 14. Total R&D spending by Victorian companies (2015)


Source: NHMRC

https://www.nhmrc.gov.au/grants-funding/outcomes-funding-rounds

https://www.nhmrc.gov.au/grants-funding/outcomes-funding-rounds

Pre-clinical and clinical assets in Victoria

ASSETS BY THERAPEUTIC AREA

Victoria’s strengths in therapeutic development lie in the oncology, infection and immunity and cardiovascular disease areas, see Figure 15.10 Therapeutic areas covered in "other" include endocrinology and regenerative medicine, as well as orphan diseases.

ASSETS: MEDTECH VS DRUG DEVELOPMENT

The majority of clinical assets in development are in pharmaceuticals as opposed to medical devices. This is consistent with the relevant size of the sectors, see Figure 16.11

10 State Government of Victoria, Life Sciences Pre-Clinical and Clinical Development Programs, Melbourne Australia, June 2016 Commercial -in-Confidence.

11 State Government of Victoria, Life Sciences Pre-Clinical and Clinical Development Programs, Melbourne Australia, June 2016 Commercial -in-Confidence.

0

20

40

60

80

100

120

Drug Development Medical Devices

No

of a

sset

s u

nd

er d

evel

op

men

t

ClinicalPre-clinical

103

56

34

112

0

5

10

15

20

25

30

35

40

45

50

No.

of c

linic

al a

sset

s u

nd

er d

evel

opm

ent

22

13

Infe

ctio

us

dis

ease

s

12.59.5

Au

toim

mu

nit

y &

infla

mm

ati

on

69

Met

ab

olic

dis

ord

ers

9.58

Neu

rosc

ien

ce

16

6

Res

pir

ato

ry

48

35

Oth

er

ClinicalPre-clinical

25

On

colo

gy

36

24

Ca

rdio

vasc

ula

r4.5

16.5

Pa

in

4.5

Figure 15. Victorian strengths (June 2016)

Figure 16. Asset development in Victoria – drugs and medical devices (June 2016)




Further information

Further information on the Victorian Government’s medtech and pharmaceuticals sector strategy and current support programs for industry is available at business.vic.gov.au/ support-for-your-business/future-industries.

IDT Australia

Lab 22, CSIRO

http://www.business.vic.gov.au/support-for-your-business/future-industries



Notes on methodology

The variety of sources utilised to produce the report is indicative of the difficulty of assembling the correct set of metrics for assessing the size and economic impact of the sector. In addition, the data sources cover different time points. In 2016, the Department of Economic Development, Jobs, Transport and Resources (DEDJTR) commissioned the Centre for Transformative Innovation (CTI) at Swinburne University to analyse the impact of the medtech and pharmaceuticals sector on the Victorian economy.

The CTI Report12 utilised a novel new methodology, drawing on de-identified firm-level financial data from Business Activity Statements (BAS) collected by the Australian Taxation Office (ATO) and made available by the Australian Bureau of Statistics (ABS), as the BLADE dataset, the most recent data available for analysis relates to financial year 2013-14.13

12 Centre for Transformative Innovation (February, 2017), Economic Impact Analysis – Victorian Medical Technologies & Pharmaceuticals Sector.

13 Due to a lag in availability, the data is from 2013-14

The sector does not fit one single standard industrial classification. It was therefore not possible to evaluate the complete size of the sector using detailed “off-the-shelf” statistics published by the ABS. To measure the impact of the sector, the CTI identified 651 firms with relevant activities in the sector.14 The economic impact of the sector was then measured by aggregating the activity of these firms.15

To enable a more complete picture of the economic impact of the sector on the Victorian economy, DEDJTR also commissioned Blake Industry & Market Analysis Pty Ltd (“Blake”) to furnish a complementary and commercial in confidence report for FY201516 using a different methodology and providing a greater focus on the various companies in the sector. Over 200 businesses in the sector were surveyed and additional information was retrieved through publicly available documents, including company reports, news articles and regulatory filings, as well as financial analysis metrics. In addition, export data has been sourced from the IHS Global Trade Atlas.17

14 A complete list of the firms included in the analysis is included in Appendix A of the CTI Report.

15 The main caveat to the measured direct impact is that operations in Victoria of firms that are based in other states have not been included. Similarly, no adjustment was made for any possible economic activity outside Victoria by Victorian firms. This means the estimates of economic impact presented are conservative.

16 Blake Industry & Market Analysis Pty Ltd (21 October, 2016), Medical Technology & Pharmaceutical Sector 2015 Final Annual Report. Commercial in confidence.

17 IHS Global Trade Atlas: Global Import/Export Commodity Trade Data, 2016.

Imagining and Medical Beamline, Australian Synchrotron, Australian Nuclear Science and Technology Organisation

DE

DJ

TR

10

875

_6/1

7

Documents

STATE OF THE SECTOR - djpr.vic.gov.au · Number of listed Victorian life science companies (2015) 15 Figure 12. Capitalisation of listed Victorian life science companies excluding